利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

110 条记录 (耗时 0.074 秒)

    PYRIMIDINEDIONE DERIVATIVES AND METHODS OF USE THEREOF
    23.
    发明申请
    PYRIMIDINEDIONE DERIVATIVES AND METHODS OF USE THEREOF 审中-公开
    吡咯烷酮衍生物及其使用方法

    公开(公告)号：US20100144764A1

    公开(公告)日：2010-06-10

    申请号：US12594969

    申请日：2008-04-09

    申请人： Xianhai Huang ,  Anandan Palani ,  Robert G. Aslanian

    发明人： Xianhai Huang ,  Anandan Palani ,  Robert G. Aslanian

    IPC分类号： A61K31/519 ,  C07D487/04 ,  A61P3/00 ,  A61P9/00 ,  A61P11/00 ,  A61P35/00 ,  A61P25/00 ,  A61P29/00 ,  A61P1/00 ,  A61P3/10

    CPC分类号： C07D487/04

    摘要： The present invention relates to Pyrimidinedione Derivatives, compositions comprising a Pyrimidinedione Derivative and methods for using the Pyrimidinedione Derivatives for treating or preventing a metabolic disorder, dyslipidemia, a cardiovascular disease, a neurological disorder, a hematological disease, cancer, inflammation, a respiratory disease, a gastroenterological disease, diabetes, a diabetic complication, obesity, an obesity-related disorder or non-alcoholic fatty liver disease.

    摘要翻译： 本发明涉及嘧啶二酮衍生物，包含嘧啶二酮衍生物的组合物和使用嘧啶二酮衍生物治疗或预防代谢紊乱，血脂异常，心血管疾病，神经障碍，血液病，癌症，炎症，呼吸系统疾病， 胃肠疾病，糖尿病，糖尿病并发症，肥胖，肥胖相关病症或非酒精性脂肪性肝病。

    Piperidine derivatives useful as CCR5 antagonists
    25.
    发明授权
    Piperidine derivatives useful as CCR5 antagonists 有权
    哌啶衍生物可用作CCR5拮抗剂

    公开(公告)号：US06387930B1

    公开(公告)日：2002-05-14

    申请号：US09562815

    申请日：2000-05-01

    申请人： Bahige M. Baroudy ,  John W. Clader ,  Hubert B. Josien ,  Stuart W. McCombie ,  Brian A. McKittrick ,  Michael W. Miller ,  Bernard R. Neustadt ,  Anandan Palani ,  Ruo Steensma ,  Jayaram R. Tagat ,  Susan F. Vice ,  Mark A. Laughlin

    发明人： Bahige M. Baroudy ,  John W. Clader ,  Hubert B. Josien ,  Stuart W. McCombie ,  Brian A. McKittrick ,  Michael W. Miller ,  Bernard R. Neustadt ,  Anandan Palani ,  Ruo Steensma ,  Jayaram R. Tagat ,  Susan F. Vice ,  Mark A. Laughlin

    IPC分类号： C07D40104

    CPC分类号： C07D401/14 ,  C07D211/58 ,  C07D413/14 ,  C07D417/14

    摘要： The use of CCR5 antagonists of the formula or a pharmaceutically acceptable salt thereof, wherein X is —C(R13)2—, —C(R13)(R19)—, —C(O)—, —O—, —NH—, —N(alkyl)—, R is optionally substituted phenyl, pyridyl, thiophenyl or naphthyl; R1 is H, alkyl or alkenyl; R2 is optionally substituted phenyl, phenylalkyl, heteroaryl or heteroarylalkyl, naphthyl, fluorenyl or diphenylmethyl; R3 is optionally substituted phenyl, heteroaryl or naphthyl; R4 is H, alkyl, fluoro-alkyl, cyclopropylmethyl, —CH2CH2OH, —CH2CH2—O-alkyl, —CH2C(O)—O-alkyl, —CH2C(O)NH2, —CH2C(O)—NHalkyl or —CH2C(O)—N(alkyl)2; R19 is optionally substituted phenyl, heteroaryl or naphthyl, cycloalkyl, cycloalkylalkyl or alkoxyalkyl; and R5, R13, R14, R15 and R16 are hydrogen or alkyl for the treatment of HIV, solid organ transplant rejection, graft v. host disease, arthritis, rheumatoid arthritis, inflammatory bowel disease, atopic dermatitis, psoriasis, asthma, allergies or multiple sclerosis is disclosed, as well as novel compounds, pharmaceutical compositions comprising them, and the combination of CCR5 antagonists of the invention in combination with antiviral agents useful in the treatment of HIV or agents useful in the treatment of inflammatory diseases.

    摘要翻译： 使用下式的CCR5拮抗剂或其药学上可接受的盐，其中X是-C（R 13）2 - ， - C（R 13）（R 19） - ， - C（O） - ， - O - N（烷基） - ，R是任选取代的苯基，吡啶基，噻吩基或萘基; R1是H，烷基或烯基; R2是任选取代的苯基，苯基烷基，杂芳基或杂芳基烷基，萘基，芴基或二苯基甲基; R 3是任选取代的苯基， 杂芳基或萘基; R4是H，烷基，氟代烷基，环丙基甲基，-CH2CH2OH，-CH2CH2-O-烷基，-CH2C（O）-O-烷基，-CH2C（O）NH2，-CH2C（O） 或-CH 2 C（O）-N（烷基）2; R 19是任选取代的苯基，杂芳基或萘基，环烷基，环烷基烷基或烷氧基烷基; 和R 5，R 13，R 14，R 15和R 16是氢或烷基，用于治疗HIV，实体器官移植排斥，移植物抗宿主病，关节炎，类风湿性关节炎，炎性肠病，特应性皮炎，牛皮癣，哮喘，过敏或多发性硬化 以及新化合物，包含它们的药物组合物，以及本发明的CCR5拮抗剂与可用于治疗HIV的抗病毒剂或可用于治疗炎性疾病的药剂的组合。